Retinoblastoma

Group Elite Raises Over $72,000 for SickKids Clinical Trial

Retrieved on: 
Thursday, December 15, 2022

LAVAL, QC and GREENWOOD VILLAGE, Colo., Dec.15, 2022 /PRNewswire-PRWeb/ -- The team at Group Elite is proud to announce that their recent campaign raised over $64,000 for the SickKids Foundation, in support of a retinoblastoma clinical trial led by The Hospital for Sick Children (SickKids). As part of their 10-Year Anniversary celebration, Group Elite created a campaign called, "We Have the Power" to raise money to support retinoblastoma research. The campaign had an initial goal of $10,000 and generous donations from employees and global partners were made in Canada and the United States.

Key Points: 
  • Group Elite is proud to announce that their recent campaign raised over $72,000 for the SickKids Foundation, in support of a retinoblastoma clinical trial led by The Hospital for Sick Children (SickKids)
    LAVAL, QC and GREENWOOD VILLAGE, Colo., Dec.15, 2022 /PRNewswire-PRWeb/ -- The team at Group Elite is proud to announce that their recent campaign raised over $64,000 for the SickKids Foundation, in support of a retinoblastoma clinical trial led by The Hospital for Sick Children (SickKids).
  • As part of their 10-Year Anniversary celebration, Group Elite created a campaign called, "We Have the Power" to raise money to support retinoblastoma research.
  • "The generosity of our extended Group Elite family astounds me," shared Michael Moore.
  • For over 3 years, the Group Elite team continues an indirect relationship with a special girl from Montreal named Ella suffering from retinoblastoma.

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

Retrieved on: 
Thursday, December 1, 2022

ADX-2191, which has received FDA Orphan Drug Designation for the treatment of primary vitreoretinal lymphoma, is a novel, vitreous-compatible formulation of methotrexate.

Key Points: 
  • ADX-2191, which has received FDA Orphan Drug Designation for the treatment of primary vitreoretinal lymphoma, is a novel, vitreous-compatible formulation of methotrexate.
  • ADX-2191 has received FDA Orphan Drug Designation for the prevention of proliferative vitreoretinopathy, and the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
  • Primary vitreoretinal lymphoma is a rare, aggressive, and potentially fatal retinal cancer that is diagnosed in approximately 300 to 600 patients in the United States per year.
  • Data on file; Primary Vitreoretinal Lymphoma by D. J. Wilson on AAO EyeWiki; M. Sagoo, Survey of Ophthalmology (2014); Grimm et.

Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results

Retrieved on: 
Thursday, November 10, 2022

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the quarter ended September 30, 2022, and provided a corporate update.
  • We are encouraged by our clinical results demonstrating the therapeutic potential of Therivas oncology-focused platform, said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
  • In October 2022, the Company rebranded as Theriva Biologics and began trading on NYSE American under the new ticker symbol TOVX.
  • ET to review the third quarter 2022 operational highlights and financial results.

DIAGNOS Enters the Retinal Diagnostics Market With its New 3D Image Analysis Technology

Retrieved on: 
Thursday, October 27, 2022

DIAGNOS is pushing the boundaries of the practice with a deep learning-powered technology capable of diagnosing retinal conditions such as Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma, Macular Edema, Retinal Cancer, and other retinal and macular diseases.

Key Points: 
  • DIAGNOS is pushing the boundaries of the practice with a deep learning-powered technology capable of diagnosing retinal conditions such as Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma, Macular Edema, Retinal Cancer, and other retinal and macular diseases.
  • The multimodal data analysis tools developed by DIAGNOS take advantage of the most recent advancements in ophthalmic science.
  • Combining data fetched from retinal images and optical coherence tomography (OCT) scans, DIAGNOS uses the most accurate technologies that exist for retinal diagnostics.
  • The technology is more precise than MRI and ultrasound scanning, it is non-invasive, and integrates the analysis of 3D cross-sectional images of the retina.

BuzzRx® Grants 600th Wish With Make-A-Wish®

Retrieved on: 
Tuesday, October 11, 2022

FORT LAUDERDALE, Fla., Oct. 11, 2022 /PRNewswire/ -- Today, BuzzRx, the only provider of free prescription discount cards benefiting nonprofits year-round, announced the company has reached a milestone of donating $6 million to Make-A-Wish, which equates to 600 life-changing wishes for children battling critical illnesses. In the past year alone, the company has donated more than $500,000 to help grant the wish of every eligible child. Continuing to grant wishes is critical to supporting BuzzRx's mission of helping make communities healthier.

Key Points: 
  • In the past year alone, the company has donated more than $500,000 to help grant the wish of every eligible child.
  • To mark the company's 600th wish milestone, BuzzRx helped grant 4-year-old Lydia's wish to meet her favorite animals.
  • BuzzRx Co-founder & CEO Matt Herfield said, "The entire BuzzRx team is beyond thrilled to help grant Lydia's wish in celebration of this donation milestone.
  • Generous individuals and corporate partners fund our wish pipeline entirely," said Richard K. Davis, president and CEO of Make-A-Wish America.

Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma

Retrieved on: 
Friday, September 30, 2022

Preclinical results were featured in an oral presentation at the SIOP 2022 Congress of the International Society of Pediatric Oncology, being held in Barcelona, Spain from September 28-October 1, 2022.

Key Points: 
  • Preclinical results were featured in an oral presentation at the SIOP 2022 Congress of the International Society of Pediatric Oncology, being held in Barcelona, Spain from September 28-October 1, 2022.
  • The exciting new data presented at SIOP demonstrate that administration of VCN-01 in combination with topotecan chemotherapy may improve VCN-01 activity against retinoblastoma, said Manel Cascall, Ph.D., General Director of Synthetic Biologics European Subsidiary.
  • Sequential administration of intratumoral VCN-01 followed by systemic topotecan significantly increased median ocular survival, compared to VCN-01 alone (p =0.0364).
  • Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need.

Children's Hospital Los Angeles Identifies Molecular Markers to Increase Precision in Treatment of Retinoblastoma

Retrieved on: 
Monday, September 26, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220926005151/en/
    Jesse Berry, MD, surgeon, ocular oncologist and researcher at Children's Hospital Los Angeles (Photo: Business Wire)
    Because retinoblastoma occurs at the back of the eye, it is not readily observable.
  • Historically, the child would be presumed to have retinoblastoma, which is a genetic condition, and treated without a definitive diagnosis.
  • Founded in 1901, Childrens Hospital Los Angeles is the largest provider of care for children in Los Angeles County and is ranked the No.
  • The hospital also is home to the largest pediatric residency training program at a freestanding childrens hospital in the Western United States.

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Retrieved on: 
Monday, September 5, 2022

ROCKVILLE, Md., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced a presentation of initial data from a Phase 1 investigator-sponsored study evaluating VCN-01 in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). Data will be featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress, being held both virtually and in Paris from September 9-13, 2022.

Key Points: 
  • Data will be featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress, being held both virtually and in Paris from September 9-13, 2022.
  • Further, these results provide valuable dose-finding context and build upon our compelling foundation of data that highlight VCN-01s differentiated mechanism of action that may transform cancer therapy.
  • Pharmacokinetics (PK) and pharmacodynamics (PD): Based on toxicology and PK/PD analysis the recommended Phase 2 dose is 1x1013 viral particles (vp)/patient.
  • Biological activity: Sustained blood levels of VCN-01 viral genomes and increased serum hyaluronidase levels were maintained for over six weeks.

Medical Cyclotron Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Type [Ring Cyclotron, and Azimuthally Varying Field], Capacity, and End User - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 24, 2022

The "Medical Cyclotron Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type [Ring Cyclotron, and Azimuthally Varying Field], Capacity, and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Cyclotron Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type [Ring Cyclotron, and Azimuthally Varying Field], Capacity, and End User" report has been added to ResearchAndMarkets.com's offering.
  • However, the high cost of procedures and lack of expertise are restricting the growth of the medical cyclotron market.
  • Based on type, the medical cyclotron market is segmented into ring cyclotron and azimuthally varying fields (AVF).
  • The key company initiating a distinct growth strategy will have a high potential to grow the global medical cyclotron market.

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

Retrieved on: 
Thursday, August 11, 2022

ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.

Key Points: 
  • On July 25, 2022, the Companys common stock began trading on a split-adjusted basis.
  • Cash and cash equivalents totaled $52.3 million as of June 30, 2022, compared to $67.3 million as of December 31, 2021.
  • ET today to review second quarter 2022 operational highlights and financial results.
  • Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need.